These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 35859133)

  • 1. Assessment of disease outcome measures in systemic sclerosis.
    Lafyatis R; Valenzi E
    Nat Rev Rheumatol; 2022 Sep; 18(9):527-541. PubMed ID: 35859133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development.
    Castelino FV; Varga J
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1077-90. PubMed ID: 24168414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
    Gordon JK; Domsic RT
    Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial design in scleroderma: where are we and where do we go next?
    Chung L; Denton CP; Distler O; Furst DE; Khanna D; Merkel PA;
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S97-102. PubMed ID: 22691217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs in phase I and phase II clinical trials for systemic sclerosis.
    Chung MP; Chung L
    Expert Opin Investig Drugs; 2020 Apr; 29(4):349-362. PubMed ID: 32178544
    [No Abstract]   [Full Text] [Related]  

  • 6. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease.
    Martyanov V; Kim GJ; Hayes W; Du S; Ganguly BJ; Sy O; Lee SK; Bogatkevich GS; Schieven GL; Schiopu E; Marangoni RG; Goldin J; Whitfield ML; Varga J
    PLoS One; 2017; 12(11):e0187580. PubMed ID: 29121645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative stress in the pathogenesis of systemic scleroderma: An overview.
    Vona R; Giovannetti A; Gambardella L; Malorni W; Pietraforte D; Straface E
    J Cell Mol Med; 2018 Jul; 22(7):3308-3314. PubMed ID: 29664231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic sclerosis. A clinical overview.
    Generini S; Fiori G; Moggi Pignone A; Matucci Cerinic M; Cagnoni M
    Adv Exp Med Biol; 1999; 455():73-83. PubMed ID: 10599326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.
    Streicher K; Sridhar S; Kuziora M; Morehouse CA; Higgs BW; Sebastian Y; Groves CJ; Pilataxi F; Brohawn PZ; Herbst R; Ranade K
    Arthritis Rheumatol; 2018 Dec; 70(12):2087-2095. PubMed ID: 29956883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging biomarkers in systemic sclerosis.
    Manetti M
    Curr Opin Rheumatol; 2016 Nov; 28(6):606-12. PubMed ID: 27380110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Existing and novel biomarkers for precision medicine in systemic sclerosis.
    Wermuth PJ; Piera-Velazquez S; Rosenbloom J; Jimenez SA
    Nat Rev Rheumatol; 2018 Jul; 14(7):421-432. PubMed ID: 29789665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrotics in systemic sclerosis.
    Martin-Lopez M; Carreira PE
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101671. PubMed ID: 33839046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting very early systemic sclerosis: a case-based review.
    Melissaropoulos K; Kraniotis P; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
    Rheumatol Int; 2019 Nov; 39(11):1961-1970. PubMed ID: 31254002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
    Khanna D; Brown KK; Clements PJ; Elashoff R; Furst DE; Goldin J; Seibold JR; Silver RM; Tashkin DP; Wells AU
    Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S55-62. PubMed ID: 20576216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers in systemic sclerosis.
    Skaug B; Assassi S
    Curr Opin Rheumatol; 2019 Nov; 31(6):595-602. PubMed ID: 31436584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs and therapeutics for systemic sclerosis.
    Lee JJ; Pope JE
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on recent randomized clinical trials in systemic sclerosis.
    Boleto G; Avouac J; Allanore Y
    Joint Bone Spine; 2021 Oct; 88(5):105184. PubMed ID: 33887472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.